Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Most common side effects of mirdametinib in adultsAccording to clinical trial data for mirdametinib, the most common adverse reactions in adult patients mainly include five aspects···【more】
Article source：Captain MedicineRelease date：2026-06-09Recommended：10
What is Mirdametinib?Mirdametinib is a prescription medicine specifically used to treat adults and pediatric patients aged 2 years and older who have neurofibromatosis type 1 (NF1)···【more】
Article source：Captain MedicineRelease date：2026-06-09Recommended：8
Effect of Other Drugs on RepotrectinibAvoid concomitant use of repotrectinib with P-glycoprotein inhibitors, strong or moderate CYP3A inducers, and strong or moderate CYP3A inhibit···【more】
Article source：Captain MedicineRelease date：2026-06-05Recommended：40
Common Adverse Reactions of RepotrectinibThe safety of Repotrectinib was evaluated in 426 patients in the TRIDENT-1 study. Overall, most adverse reactions were Grade 1 or 2, but so···【more】
Article source：Captain MedicineRelease date：2026-06-05Recommended：41
Repotrectinib Use in Special PopulationsBased on literature reports of human congenital mutations leading to altered tropomyosin receptor tyrosine kinase signaling, animal study re···【more】
Article source：Captain MedicineRelease date：2026-06-04Recommended：48
Are the side effects of Repotrectinib severe?Repotrectinib can cause myalgia, with or without elevated creatine phosphokinase levels. In clinical trials, the incidence of myalgia w···【more】
Article source：Captain MedicineRelease date：2026-06-04Recommended：41
Adverse Reactions of RepotrectinibIn the TRIDENT-1 study, among 426 patients treated with repotrectinib, up to 77% experienced central nervous system adverse reactions, including d···【more】
Article source：Captain MedicineRelease date：2026-06-03Recommended：42
Detailed Indications for RepotrectinibOne core indication of Repotrectinib is the treatment of ROS1-positive non-small cell lung cancer. Specifically, it is indicated for adult pat···【more】
Article source：Captain MedicineRelease date：2026-06-03Recommended：46
Risk Identification and Management of Serious Side Effects of RepotrectinibRepotrectinib may cause serious side effects, among which central nervous system issues require particula···【more】
Article source：Captain MedicineRelease date：2026-06-02Recommended：56
Special Populations for RepotrectinibIf you are pregnant or planning to become pregnant, you must inform your doctor. Repotrectinib may cause harm to an unborn baby. Women of child···【more】
Article source：Captain MedicineRelease date：2026-06-02Recommended：59
What is Repotrectinib?Repotrectinib (generic name: repotrectinib) is an oral prescription medicine used to treat two specific types of cancer. The first is ROS1-positive non-small ···【more】
Article source：Captain MedicineRelease date：2026-06-01Recommended：55
Tivozanib: Rare but Serious Complications and Patient Safety StrategiesReversible posterior leukoencephalopathy syndrome (PRES) is a rare but serious neurological complication, occ···【more】
Article source：Captain MedicineRelease date：2026-05-29Recommended：60
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4242025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6062024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：702026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3922025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4062025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4002025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4532025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3702025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
